What is Quantum Genomics?
Headquartered in Paris, France, and established in 2005, Quantum Genomics operates at the intersection of advanced neuroscience and cardiology. The company is primarily recognized for its development of a novel class of medications designed to address unmet needs in cardiovascular health. By targeting brain aminopeptidase A inhibition, the firm aims to provide transformative treatment options for patients suffering from hypertension and heart failure. This focus on BAPAI technology positions Quantum Genomics as a critical player in the global biopharma landscape, bridging the gap between complex molecular research and scalable clinical applications.
How much funding has Quantum Genomics raised?
Quantum Genomics has raised a total of $18.3M across 3 funding rounds:
Debt
$1.8M
Stock Offering
$16M
Other Financing Round
$539K
Debt (2021): $1.8M with participation from Bpifrance
Stock Issuance/Offering (2022): $16M, investors not publicly disclosed
Other Financing Round (2024): $539K, investors not publicly disclosed
Key Investors in Quantum Genomics
Bpifrance
A French public investment bank that supports companies at every stage of development through credit, guarantees, and equity, with a strong focus on innovation and international expansion.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Quantum Genomics?
With the recent influx of capital, Quantum Genomics is well-positioned to accelerate its clinical development programs and expand its international footprint. The strategic allocation of these funds will likely prioritize the advancement of late-stage trials and the optimization of manufacturing processes for its lead therapeutic candidates. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward regulatory milestones and potential commercialization partnerships. Investors and industry analysts will be closely monitoring the firm's ability to translate its scientific innovation into tangible market value, particularly as it navigates the competitive landscape of cardiovascular medicine.
See full Quantum Genomics company page
